Science you can see. Beauty you can feel.
Daxxify DaxibotulinumtoxinA
Long-Duration - Glabellar Lines - Peptide-Stabilized

Buy Daxxify Wholesale NYC

DaxibotulinumtoxinA | Wholesale Per Vial

From $349.00 / vial

4.9 / 5.0 - 214 reviews

Select Products

Daxxify DaxibotulinumtoxinA 100 U VialWholesale price per vial
$349.00
0
Daxxify DaxibotulinumtoxinA 100 U - 3 Vial PackWholesale price per pack
$980.00
0
Your Selection
Order Total$0.00

The world's longest-lasting FDA-approved neurotoxin - results lasting 6 months or more in the majority of clinical trial patients

Daxxify (DaxibotulinumtoxinA-lanm) is Revance Therapeutics' breakthrough neurotoxin and the only botulinum toxin type A stabilized with a proprietary peptide exchange technology (PRTX) rather than human serum albumin. This innovation allows for a stable, pure formulation with an extended duration of action. In pivotal clinical trials, the majority of patients maintained a none or mild severity score at 6 months, making Daxxify the longest-lasting FDA-approved neurotoxin available.

  • FDA-approved for glabellar frown lines - longest-lasting on the market
  • Clinical results lasting 6+ months in majority of trial participants
  • Stabilized with peptide technology - no human albumin required
Delivery
Fast Tracked Priority
Sourcing
USA Genuine Products
Support
Friendly Customer Care
Find a Specialist Near You

Also see: Botox Cosmetic | Official info: Daxxify.com

The Next Generation of Neurotoxin Longevity

Daxxify (DaxibotulinumtoxinA-lanm) represents a genuine innovation in neurotoxin science. Developed by Revance Therapeutics and FDA-approved in 2022, it is the first and only botulinum toxin type A stabilized with a proprietary peptide - the PRTX peptide excipient - rather than human serum albumin. This eliminates the need for blood-derived stabilizers and enables an extended tissue residence time unlike any other toxin on the market.

In the pivotal SAKURA clinical program, the majority of Daxxify patients maintained at least a none or mild glabellar severity score at 6 months - a benchmark no other FDA-approved neurotoxin has achieved. For patients who want fewer appointments and longer-lasting results, Daxxify is a category-defining solution.

Key Benefits

  • 01FDA-approved 2022 - the newest and longest-lasting neurotoxin available
  • 02Results lasting 6 months or more in the majority of trial patients (SAKURA studies)
  • 03PRTX peptide stabilization - no human albumin, reduced visit frequency
  • 04Precision injection with standard onset (3-7 days) and natural-looking results
  • 05Ideal for patients seeking fewer treatments per year and long-term value

Product Specifications

Product NameDaxxify
Active IngredientDaxibotulinumtoxinA-lanm (Botulinum Toxin Type A)
Vial Size100 units per vial
ManufacturerRevance Therapeutics
FDA Approval2022 (glabellar frown lines)
Onset of Action3-7 days; full effect at 2 weeks
Duration6+ months (median in SAKURA trials)
StabilizerPRTX peptide excipient (no human albumin)

Results Timeline

Day 3-7

Initial muscle relaxation and visible softening of glabellar frown lines begin.

Week 2

Full effect established. Frown lines are significantly smoothed with natural-looking softening.

Month 6+

The majority of patients maintained results at 6 months - a clinical milestone no other FDA-approved neurotoxin has matched.

Current Pricing

Wholesale prices listed per vial.

Daxxify DaxibotulinumtoxinA 100 U VialWholesale price per vial
$349.00
Daxxify DaxibotulinumtoxinA 100 U - 3 Vial PackWholesale price per pack
$980.00

Pricing is subject to change. For licensed practitioners only.

Step 1: Consultation and Facial Assessment

Your Sculptra NYC practitioner evaluates your glabellar muscle activity, existing line depth, and overall facial anatomy. A personalized injection plan is created to maximize the longevity and precision of your Daxxify treatment.

Step 2: Precision Injection

Daxxify is administered with fine-gauge needles into the corrugator and procerus muscles responsible for frown lines. The procedure takes 15-20 minutes. Units are dosed in the same manner as Botox, allowing a familiar experience for both practitioners and patients.

Step 3: Extended Neuromuscular Blockade

DaxibotulinumtoxinA blocks acetylcholine release at the neuromuscular junction. The PRTX peptide stabilizer enables the toxin to remain active at the injection site longer than any other currently approved neurotoxin, translating to results that last significantly beyond the 3-4 month window of traditional products.

Step 4: Fewer Treatments, Lasting Results

With results lasting 6 months or more for most patients, many Daxxify patients need only 2 treatments per year instead of the 3-4 needed with shorter-acting neurotoxins. This offers significant long-term value for high-volume practices and frequent treatment patients.

Who Is Daxxify Right For?

Daxxify is ideal for adults with moderate to severe glabellar frown lines who want the maximum duration from their neurotoxin treatment. It is particularly well-suited for busy patients who prefer fewer appointments per year, and for those who have been satisfied with traditional neurotoxins but want results that simply last longer.

Practitioners also benefit from Daxxify in high-volume settings where patient satisfaction is tied to treatment frequency. Fewer retreatment cycles can mean higher patient retention and overall satisfaction scores.

Ideal Candidates

  • ?Adults with moderate to severe glabellar frown lines
  • ?Patients who want fewer annual treatments and longer-lasting results
  • ?Satisfied neurotoxin users seeking the next level of longevity
  • ?Patients who prefer albumin-free, peptide-stabilized formulations

Not Recommended For

  • -Individuals with known hypersensitivity to botulinum toxin or product excipients
  • -Patients with neuromuscular conditions such as myasthenia gravis or ALS
  • -Pregnant or breastfeeding women
  • -Patients with only static (at-rest) wrinkles better addressed by fillers

A consultation with a licensed Sculptra NYC specialist is required to determine candidacy. See Important Safety Information below.

In the SAKURA 1 and SAKURA 2 pivotal trials, the majority of patients maintained a none or mild glabellar severity score at 6 months. Some patients experienced results lasting up to 9 months. This is significantly longer than the 3-4 months typical of Botox, Dysport, or Xeomin.

Yes. Daxxify received FDA approval in September 2022 after demonstrating both safety and efficacy in clinical trials. Its PRTX peptide stabilizer has been well-tolerated. Adverse events are similar to other neurotoxins and are generally mild and transient.

Both are botulinum toxin type A products approved for glabellar lines. Daxxify uses the same unit system as Botox and has a similar onset (3-7 days). The key difference is duration: Daxxify lasts roughly 6 months in most patients versus 3-4 months for Botox. Daxxify is also stabilized with a peptide rather than human albumin.

Yes. Daxxify treats dynamic glabellar lines while fillers like Juvederm or Sculptra PLLA address volume loss and static wrinkles. Combining Daxxify's extended duration with a collagen stimulator like Sculptra creates a comprehensive, long-lasting facial rejuvenation protocol.

No significant downtime. Most patients return to normal activities immediately. Minor injection site reactions (redness, swelling) typically resolve within 30 minutes. Avoid strenuous exercise, lying flat, and touching treated areas for 4 hours after the procedure.

You May Also Like
Botox Cosmetic OnabotulinumtoxinA
Botulinum Toxin Type A

Botox Cosmetic
OnabotulinumtoxinA - Allergan

The gold standard - 20+ years of proven safety and precision results

From $267.00 / vial

View DetailsOrder Now
[Image: Dysport 300U Vial]
Botulinum Toxin Type A

Dysport
AbobotulinumtoxinA - Galderma

Faster onset and broad diffusion - preferred for large treatment areas

From $229.00 / vial

View DetailsOrder Now
[Image: Jeuveau 100U Vial]
Botulinum Toxin Type A

Jeuveau
PrabotulinumtoxinA - Evolus

Hi-Pure manufacturing for consistent potency - modern Botox alternative

From $219.00 / vial

View DetailsOrder Now

Important Safety Information

INDICATIONS: Daxxify (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

CONTRAINDICATIONS: Daxxify is contraindicated in patients with a known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, and in patients with infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS: Daxxify should only be administered by licensed healthcare professionals. Units of Daxxify are not interchangeable with other botulinum toxin products. Risk of distant spread of toxin effect. Effects may last longer than traditional neurotoxins.

MOST COMMON ADVERSE EVENTS: Headache, eyelid ptosis, facial paresis, injection site bruising, eyelid edema. Most events are mild to moderate and resolve without intervention.

References: 1. Daxxify US Prescribing Information, Revance Therapeutics, 2022. 2. SAKURA 1 & SAKURA 2 Phase 3 Clinical Trials. 3. FDA BLA 761201.